[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345076-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345076-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","therapeutic-strategies-to-overcome-payload-resistance-of-trastuzumab-deruxtecan-in-her2-positive-cancers","Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers","","Antibody-drug conjugates (ADCs) represent a targeted cancer therapy class, with trastuzumab deruxtecan (T-DXd) acting as a HER2-directed ADC. Acquired resistance can limit long-term benefit, prompting investigation of resistance mechanisms. HER2-amplified gastric xenografts (N87 AR) and leptomeningeal carcinomatosis models (Calu-3 AR) were used to establish resistant cell lines. Resistance showed cross-resistance to T-DXd, payload DXd, and SN-38, associated with upregulation of ABCG2 and ABCB1. Inhibiting or knocking down these transporters restored T-DXd sensitivity, and BB-1701 demonstrated anti-tumor activity in resistant settings. Targeting drug efflux and using alternative payloads are proposed strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/therapeutic-strategies-to-overcome-payload-resistance-of-trastuzumab-deruxtecan-in-her2-positive-cancers/345076/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/therapeutic-strategies-to-overcome-payload-resistance-of-trastuzumab-deruxtecan-in-her2-positive-cancers/345076.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the document address regarding T-DXd therapy?","Question",{"text":63,"@type":64},"The document addresses acquired resistance to trastuzumab deruxtecan (T-DXd) that limits long-term efficacy in HER2-positive cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were T-DXd-resistant cell models established?",{"text":68,"@type":64},"Resistant cell lines were derived from HER2-amplified gastric xenografts (N87 acquired resistance) and leptomeningeal carcinomatosis-derived lung cancer cells (Calu-3 acquired resistance).",{"name":70,"@type":61,"acceptedAnswer":71},"Which mechanisms and interventions are reported to overcome payload resistance?",{"text":72,"@type":64},"The study identifies upregulation of the drug efflux transporters ABCG2 (in N87 AR) and ABCB1 (in Calu-3 AR). Pharmacological inhibition or siRNA knockdown of these transporters restored T-DXd sensitivity, and the HER2-ADC BB-1701 showed anti-tumor effects in resistant models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345076,1790193822,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Cell,Molecular,and Stem Cell Biology  \n# Therapeutic Strategies to Overcome Payload Resistance ofTrastuzumab Deruxtecan in HER2-Positive Cancers\n\nYuya Murase¹D I Shigeki Nanjo¹I Sachiko Arai²I Sota Kondo³|Hayato Koba¹I Yifeng Liu¹I Koji Fukuda⁴D IShigeki Sato⁴I Jun Kinoshita⁵D I Noriyuki Inaki⁵I Tsukasa Ueda¹I Shunichi Nomura¹I Yuichi Tambo¹ITakahiro Shimizu¹I Masafumi Horie⁶D I Daichi Maeda⁶|Richard W.Wong²,7 I Kazuyoshi Hosomichi⁸ITakafumi Kobayashi¹I Satoshi Watanabe¹I Kenta Yamamura¹I Noriyuki Ohkura¹I Miki Abo¹I Seiji Yano¹,2  \n¹Department of Respiratory Medicine,Kanazawa University Hospital,Kanazawa,Ishikawa,Japan I 2WPI Nano Life Science Institute(WPI-NanoLSD,Kanazawa University,Kanazawa,Ishikawa,Japan I³Division of Nano Life Science,Graduate School of Frontier Science Initiative,KanazawaUniversity,Kanazawa,Ishikawa,Japan I 4Department of Medical Oncology,Cancer Research Institute,KanazawaUniversity,Kanazawa,Ishikawa,Japan I SDepartmentof Gastrointestinal Surgery,Kanazawa University Hospital,Kanazawa,ISshikawa,Japan I 6Department of Molecular and CellularPathology,Kanazawa University,Kanazawa,Ishikawa,Japan I Cell-Bionomics Research Unit,Innovative Integrated Bio-Research Core,Institute forFrontier Science Initiative,KanazawaUniversity,Kanazawa,Ishikawa,Japan ILaboratoryof Genomic Information and MedicalSciences,Department ofBiomedical Sciences,School of Life Sciences,Tokyo University of Pharmacy and Life Sciences,Tokyo,Japan  \nCorrespondence:Seiji Yano(syano@staff.kanazawa-u.ac.jp)  \nReceived:12 September 2025 I Revised:30 December 2025 |Accepted:5 January 2026  \nKeywords:ABC transporters l antibody-drug conjugate |BB-1701 |HER2I trastuzumab deruxtecan  \n## ABSTRACT\n\nAntibody-drug conjugates(ADCs)are emerging as a promising class of targeted cancer therapy.Trastuzumab deruxtecan(T-DXd),a human epidermal growth factor receptor 2(HER2)-directed ADC,has demonstrated clinical efficacy in HER2-positivegastric and breast cancers,as well as in HER2-mutant non-small cell lung cancer.However,the development of acquired resist-ance limits their long-term efficacy.To elucidate the resistance mechanism,we established T-DXd-resistant cellines derivedfrom HER2-amplified gastric xenografts(N87 acquired resistance [AR])and leptomeningeal carcinomatosis(Calu-3 AR)lungcancer cells.N87 AR cells exhibited cross-resistance to T-DXd,payload DXd,and topoisomerase I inhibitor SN-38 despite pre-served HER2 expression and intact drug internalization.As payload resistance-related molecules,ATP-binding cassette(ABC)transporter ABCG2and ABCB1 were markedly upregulated in N87 AR and Calu-3 cells,respectively.Inhibition of ABCG2 andABCB1in N87ARand Calu-3 cells,respectively,through siRNA-mediated knockdown restoredT-DXd sensitivity in both mod-els.As a strategy to overcome resistance,pharmacological inhibitors ofABCG2and ABCB1 restored the T-DXd sensitivity of N87AR and Calu-3 cells,respectively.Moreover,BB-1701,a novel HER2-ADC containing eribulin as a payload,to which N87 ARcells are sensitive,exhibited antitumoreffects in N87 AR cells in vitro and in vivo.These findings indicate that ABC transporter-mediated drugeffluxis an important mechanism underlyingT-DXd resistance in HER2-positive gastricandlung cancer models.Furthermore,our study suggests that both targeting drug efflux pathways and utilizing alternative payloads may be effectivestrategies for overcomingT-DXd resistance in HER2-positive gastric and lung cancers.  \n## 1|Introduction\n\nAntibody-drug conjugates(ADCs)are a class of anticanceragents that couple the target specificity of monoclonal antibod-ies with the cytotoxic potency of chemotherapy.A typical ADCcomprises three components:a monoclonal antibody targetinga tumor-associated antigen,a cytotoxic payload,and a chemicallinker connecting them.This targeted delivery enables selectiveaccumulation of cytotoxic agents within tumor cells,enhancingantitumor efficacy while limiting systemic toxicity relative toconventional chemotherapy [1,2]","cbCaib4DIVZDrpne","https://ap.wps.com/l/cbCaib4DIVZDrpne","pdf",2804008,14,"English","# ABSTRACT\n# 1 | Introduction\n# 2 | Materials and Methods\n## 2.1 | Establishment of T-DXd-Resistant Cell Lines","[{\"question\":\"What problem does the document address regarding T-DXd therapy?\",\"answer\":\"The document addresses acquired resistance to trastuzumab deruxtecan (T-DXd) that limits long-term efficacy in HER2-positive cancers.\"},{\"question\":\"How were T-DXd-resistant cell models established?\",\"answer\":\"Resistant cell lines were derived from HER2-amplified gastric xenografts (N87 acquired resistance) and leptomeningeal carcinomatosis-derived lung cancer cells (Calu-3 acquired resistance).\"},{\"question\":\"Which mechanisms and interventions are reported to overcome payload resistance?\",\"answer\":\"The study identifies upregulation of the drug efflux transporters ABCG2 (in N87 AR) and ABCB1 (in Calu-3 AR). Pharmacological inhibition or siRNA knockdown of these transporters restored T-DXd sensitivity, and the HER2-ADC BB-1701 showed anti-tumor effects in resistant models.\"}]","Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers | PDF",1790056438,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f7f04dc5e27e4d865c8b7320ed66c10.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6fc8d80bd0ecb8ac381827670a420602.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af2259bcff01c4c3b35e202250585e36.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83e9d5df3901e5540ea73154acccc166.webp",980,1287]